/**
 * Post: PAINS — the compounds that fake their own activity
 *
 * SEO target: "PAINS filter", "pan-assay interference compounds",
 * "frequent hitters HTS", "rhodanine PAINS", "structural alerts drug
 * discovery". Internal CTA into /studio: dock the hit, then treat a PAINS
 * substructure match as a flag to confirm with orthogonal assays.
 */

import { Link } from "react-router-dom";
import type { PostMeta } from "../types";

export const meta: PostMeta = {
  slug: "pains-pan-assay-interference-compounds",
  title: "PAINS: the compounds that fake their own activity",
  description:
    "What pan-assay interference compounds are, the chemistry behind their false hits, and why a PAINS flag is a prompt to confirm, not a verdict to discard.",
  date: "2026-05-20",
  author: "Liganx team",
  tags: ["pains", "admet", "screening", "drug-design"],
  readingMin: 5,
};

export default function Post() {
  return (
    <>
      <p className="lead">
        Some molecules look like brilliant hits in a screen and turn out to
        be brilliant liars. They light up across unrelated assays, against
        unrelated targets, not because they bind anything specifically but
        because they interfere with the readout itself. These are PAINS —
        pan-assay interference compounds — and learning to recognize them is
        one of the cheapest ways to avoid burning months chasing a hit that
        was never real.
      </p>

      <h2>Where the term comes from</h2>
      <p>
        Baell and Holloway coined PAINS in a 2010 paper that mined a large
        high-throughput screening campaign for substructures that turned up
        as &ldquo;frequent hitters&rdquo; far more often than chance allows.
        Out of that analysis came a set of substructure filters — chemical
        patterns that flag a compound as statistically likely to be a
        nuisance. The motifs became famous in their own right: rhodanines,
        phenolic Mannich bases, hydroxyphenylhydrazones, alkylidene
        barbiturates, catechols, quinones, 2-amino-3-carbonylthiophenes,
        and a handful of others. If you have done any literature screening
        triage, you have seen these scaffolds get waved off on sight.
      </p>

      <h2>Why they fool the assay</h2>
      <p>
        PAINS do not share a single mechanism. They share an outcome — a
        false positive — produced through several distinct chemical routes:
      </p>
      <ul>
        <li>
          <strong>Covalent reactivity</strong> — Michael acceptors and other
          electrophilic motifs (rhodanines, alkylidene heterocycles) react
          non-specifically with cysteine and lysine residues, knocking out
          whatever protein is in the well.
        </li>
        <li>
          <strong>Redox cycling</strong> — quinones and catechols generate
          hydrogen peroxide and reactive oxygen species in the buffer,
          which then oxidize and inactivate the target. The compound never
          touches the active site.
        </li>
        <li>
          <strong>Metal chelation</strong> — some scaffolds strip catalytic
          metal ions out of metalloenzymes, looking like inhibition that is
          really just cofactor theft.
        </li>
        <li>
          <strong>Optical interference</strong> — intrinsic fluorescence or
          strong color absorbs or emits at the assay wavelength, faking a
          signal change with no biology behind it at all.
        </li>
        <li>
          <strong>Colloidal aggregation</strong> — a related promiscuity
          mode where compounds form aggregates that sequester protein
          non-specifically. Not strictly a PAINS substructure class, but it
          rides along in the same triage conversation.
        </li>
      </ul>

      <h2>The important caveat: a flag is not a verdict</h2>
      <p>
        It is tempting to treat a PAINS match as an automatic reject, and
        plenty of reviewers do. That is a mistake. The filters were derived
        empirically from one detection technology, and they over-call: a
        substructure match means a compound <em>could</em> interfere, not
        that it <em>does</em>. Several approved drugs contain motifs a PAINS
        filter would flag. The 2017 reassessment by Baell and Nissink made
        the point sharply — the right response to a PAINS hit is not the
        delete key but an orthogonal experiment: run the assay by a second,
        mechanistically independent readout, check for redox activity, test
        for aggregation with detergent, and confirm a clean
        concentration-response. If the activity holds up across orthogonal
        methods, the compound earns its place regardless of what scaffold it
        carries.
      </p>

      <h2>Where docking fits</h2>
      <p>
        Structure-based docking and PAINS are complementary checks that
        catch different failure modes. Docking asks whether a compound can
        physically fit and score well in a defined binding pocket. A PAINS
        flag asks whether an apparent hit might be an assay artifact rather
        than a real binder. A molecule can dock beautifully and still be a
        PAINS-driven false positive in the wet lab, because the interference
        happens in the buffer, not in the pocket. Running both readouts on
        the same candidate is how you separate a genuine pose from a
        promiscuous troublemaker before you commit synthesis or assay time.
      </p>

      <h2>Try it yourself</h2>
      <p>
        <Link to="/studio" className="text-cyan-600 dark:text-cyan-400 underline">
          Open Studio
        </Link>{" "}
        and dock a candidate against your target. When you review the
        structural-alert and ADMET readout on the result, treat any
        PAINS-class substructure match the way you should treat it in real
        triage: as a prompt to design an orthogonal confirmation, not as a
        reason to delete a compound that may be perfectly real. Pairing the
        pose-level evidence from molecular docking with a structural-alert
        check is the fast way to flag a frequent-hitter scaffold before it
        costs you a synthesis cycle.
      </p>
      <p>
        Liganx is molecular docking online: free, browser-based, and built
        to put the pose score and the liability flags next to each other.
        If you want to try molecular docking on a hit you are not sure about,
        that is the fastest path.
      </p>

      <h2>Primary sources</h2>
      <ul>
        <li>
          Baell JB, Holloway GA. <em>New substructure filters for removal of
          pan assay interference compounds (PAINS) from screening libraries
          and for their exclusion in bioassays.</em> J Med Chem 53,
          2719-2740 (2010).{" "}
          <a
            href="https://doi.org/10.1021/jm901137j"
            target="_blank"
            rel="noreferrer noopener"
          >
            doi:10.1021/jm901137j
          </a>
        </li>
        <li>
          Baell J, Walters MA. <em>Chemistry: Chemical con artists foil drug
          discovery.</em> Nature 513, 481-483 (2014).{" "}
          <a
            href="https://doi.org/10.1038/513481a"
            target="_blank"
            rel="noreferrer noopener"
          >
            doi:10.1038/513481a
          </a>
        </li>
        <li>
          Baell JB, Nissink JWM. <em>Seven year itch: pan-assay interference
          compounds (PAINS) in 2017 — utility and limitations.</em> ACS Chem
          Biol 13, 36-44 (2018).{" "}
          <a
            href="https://doi.org/10.1021/acschembio.7b00903"
            target="_blank"
            rel="noreferrer noopener"
          >
            doi:10.1021/acschembio.7b00903
          </a>
        </li>
      </ul>
    </>
  );
}
